Assessing Ki67 in vivo can aid in more precise classification of breast cancer patients for optimal therapy, as Ki67 levels can predict response to systemic chemotherapy and their changes can be used to monitor therapy response [127]. This evidence concerns the gene MKI67 and breast carcinoma.